Parvovirus B19 Susceptibility among Women of Childbearing Age: A Sero-Survey in the North East of Iran

Document Type : Original Research

Authors
F. Zahedi Avval 1
M. Khazaei 2
M. Davoodian 2
L. Jarahi 3
M. Youssefi 4
1 Associate professor of clinical biochemistry, Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, IRAN
2 Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, IRAN
3 Associate professor, Department of Community Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, IRAN
4 Associate professor of clinical virology, Department of microbiology and virology, Mashhad University of Medical Sciences, Mashhad ,IRAN
10.52547/iem.7.2.155
Abstract
Backgrounds: Parvovirus B19 (B19V) infection is mainly manifested as erythema infectiosum in children. Primary B19V infection during pregnancy is accompanied by a 30% risk of fetal infection, especially in epidemic conditions. Given the important impact of parvovirus B19 infection on maternal and neonate health, this study assessed parvovirus B19 susceptibility among women of childbearing age in Mashhad, northeast Iran.

Materials & Methods: Serum samples were collected from 185 women aged 20-35 years living in Mashhad. Cluster sampling was performed in different health centers located in the city to cover the main city area. A commercial ELISA kit was used to measure IgG antibodies against B19V. This study was performed in accordance with the ethical standards mentioned in the declaration of Helsinki. Informed consent was taken from all participants. A questionnaire was filled by each participant. SPSS software Version 11.5 was used for statistical analyses.

Findings: Anti-B19 IgG was observed in about 31% of women. Seroprevalence of anti- B19 antibodies among different age groups (with 5-year intervals) was not significantly different (p=.839). Also, there was no significant difference among different city areas of Mashhad in terms of anti-B19 IgG seropositivity (.39, p>.05).

Conclusion: The prevalence of parvovirus B19 infection varies in different parts of the world. Comparing to other reports, the present study revealed a rather low immunity against parvovirus B19 among women in Mashhad. These findings highlight the potential risk of B19 infection in non-immune/susceptible mothers, which may lead to sever outcomes, especially during epidemics.

Keywords

1. Woolf AD, Campion GV, Chishick A, Wise S, Cohen BJ, Klouda PT, et al. Clinical manifestations of human parvovirus B19 in adults. Archives of internal medicine. 1989;149(5):1153-6.
2. Lehmann HW, Kühner L, Beckenlehner K, Müller-Godeffroy E, Heide K-G, Küster R-M, et al. Chronic human parvovirus B19 infection in rheumatic disease of childhood and adolescence. Journal of clinical virology. 2002;25(2):135-43.
3. Moffatt S, Tanaka N, Tada K, Nose M, Nakamura M, Muraoka O, et al. A cytotoxic nonstructural protein, NS1, of human parvovirus B19 induces activation of interleukin-6 gene expression. Journal of virology. 1996;70(12):8485-91.
4. Henriques I, Monteiro F, Meireles E, Cruz A, Tavares G, Ferreira M, et al. Prevalence of Parvovirus B19 and Hepatitis A virus in Portuguese blood donors. Transfusion and apheresis science. 2005;33(3):305-9.
5. Groeneveld K, Van Der Noordaa J. Blood products and parvovirus B19. Neth J Med. 2003;61(5):154-6.
6. Norja P, Lassila R, Makris M. Parvovirus transmission by blood products–a cause for concern? British journal of haematology. 2012;159(4):385-93.
7. Rodis JF, Quinn DL, Gary GW, Anderson LJ, Rosengren S, Cartter ML, et al. Management and outcomes of pregnancies complicated by human B19 parvovirus infection: a prospective study. American journal of obstetrics and gynecology. 1990;163(4):1168-71.
8. LaMonte AC, Paul ME, Read JS, Frederick MM, Erdman DD, Han LL, et al. Persistent parvovirus B19 infection without the development of chronic anemia in HIV-infected and-uninfected children: the Women and Infants Transmission Study. Journal of Infectious Diseases. 2004;189(5):847-51.
9. Gratacós E, Torres P-J, Vidal J, Antolín E, Costa J, Jimenez de Anta MT, et al. The incidence of human parvovirus B19 infection during pregnancy and its impact on perinatal outcome. Journal of Infectious Diseases. 1995;171(5):1360-3.
10. Daly P, Corcoran A, Mahon B, Doyle S. High-sensitivity PCR detection of parvovirus B19 in plasma. Journal of clinical microbiology. 2002;40(6):1958-62.
11. Heegaard ED, Brown KE. Human parvovirus B19. Clinical microbiology reviews. 2002;15(3):485-505.
12. Control CfD. Risks associated with human parvovirus B19 infection. MMWR Morbidity and mortality weekly report. 1989;38(6):81.
13. Babaie J, Amiri S, Mostafavi E, Hassan N, Lotfi P, Esmaeili Rastaghi AR, et al. Seroprevalence and risk factors for Toxoplasma gondii infection among pregnant women in Northeast Iran. Clinical and vaccine immunology : CVI. 2013;20(11):1771-3.
14. Erfanianahmadpoor M, Nasiri R, Vakili R, Hassannia T. Seroprevalence, transmission, and associated factors of specific antibodies against cytomegalovirus among pregnant women and their infants in a regional study. Saudi medical journal. 2014;35(4):360-4.
15. Maksheed Ma, Pacsa A, Essa SS, Ahmed MA, Monem RA, Surkouh M. The prevalence of antibody to human parvovirus B19 in pregnant women in Kuwait. Acta tropica. 1999;73(3):225-9.
16. Małafiej E, Wilczyński J, Szaflik K, Śpiewak E, Nowakowska D, Marcinek P. Analysis of complications during pregnancy in women with serological features of acute toxoplasmosis or acute parvovirosis. Ginekologia polska. 2007;78(3).
17. Zajkowska A, Garkowski A, Czupryna P, Moniuszko A, Król ME, Szamatowicz J, et al. Seroprevalence of parvovirus B19 antibodies among young pregnant women or planning pregnancy, tested for toxoplasmosis. Przegl Epidemiol. 2015;69(3):479-82.
18. Abiodun I, Opaleye OO, Ojurongbe O, Fagbami AH. Seroprevalence of parvovirus B19 IgG and IgM antibodies among pregnant women in Oyo State, Nigeria. The Journal of Infection in Developing Countries. 2013;7(12):946-50.
19. Yaegashi N, Okamura K, Hamazaki Y, Yajima A, Shiraishi H, Sugamura K. Prevalence of anti-human parvovirus antibody in pregnant women. Nihon Sanka Fujinka Gakkai Zasshi. 1990;42(2):162-6.
20. Habibzadeh S, Peeri-Doghaheh H, Mohammad-Shahi J, Mobini E, Shahbazzadegan S. The prevalence of parvovirus B19 infection among pregnant women of Ardabil in 2013. Iranian journal of microbiology. 2016;8(3):214.
21. Khameneh ZR, Hanifian H, Barzegari R, Sepehrvand N. Human parvovirus B19 in Iranian pregnant women: a serologic survey. Indian Journal of Pathology and Microbiology. 2014;57(3):442.
22. Ziyaeyan M, Rasouli M, Alborzi A. The seroprevalence of parvovirus B19 infection among to-be-married girls, pregnant women, and their neonates in Shiraz, Iran. Japanese journal of infectious diseases. 2005;58(2):95-7.
23. Siennicka J, Stefanoff P, Trzcińska A, Rosińska M, Litwińska B. Seroprevalence study of parvovirus B19 in Poland. Przeglad epidemiologiczny. 2005;60(3):571-80.
24. Emiasegen SE, Nimzing L, Adoga MP, Ohagenyi AY, Lekan R. Parvovirus B19 antibodies and correlates of infection in pregnant women attending an antenatal clinic in central Nigeria. Memórias do Instituto Oswaldo Cruz. 2011;106(2):227-31.
Infection Epidemiology and Microbiology
Volume 7, Issue 2
May 2021
Pages 155-160